Interferon-a (IFN-a), a type I IFN, is a well-known antitumoral agent. The investigation of its clinical properties in acute myeloid leukemia (AML) has been prompted by its pleiotropic antiproliferative and immune effects. So far, integration of IFN-a in the therapeutic arsenal against AML has been modest in view of the divergent results of clinical trials. Recent insights into the key pharmacokinetic determinants of the clinical efficacy of IFN along with advances in its pharmaceutical formulation, have sparked renewed interest in its use. This paper reviews the possible applicability of IFN-a in the treatment of AML and provides a rational basis to re-explore its efficacy in clinical trials.
Introduction
Despite considerable progress in its treatment, acute myeloid leukemia (AML) continues to be a challenging disease. To date, AML is still associated with a dismal prognosis with a 5-year survival rate of 26% (Altekruse et al.
1
). The overall toxicity and unsatisfying long-term efficacy of current AML treatment regimens, especially in elderly patients, provide a strong impetus to keep exploring new therapeutic options. 2, 3 The type I interferons (IFNs) are a heterogeneous group of cytokines with antiviral, antiproliferative and immunomodulatory activities. These unique biological properties have been exploited to treat a variety of clinical conditions. Two type I IFN, IFN-a and IFN-b, have been approved by the Food and Drug Administration for human use. In addition to its use as an antiviral agent in condylomata acuminata and chronic hepatitis B and C, 4, 5 IFN-a has a role as an antineoplastic agent in the treatment of several solid and hematological malignancies. 6 In the field of hematological oncology, IFN-a has shown activity in hairy cell leukemia, chronic myeloid leukemia (CML) and other myeloproliferative neoplasms. [7] [8] [9] The first suggestion of a therapeutic effect in acute myeloid malignancies dates back to 1979 (Hill et al. 10 ). Research on type I IFN in AML boomed shortly afterward, since cloning of recombinant human IFN-a in 1980 allowed the production of large amounts of the cytokine for characterization and use in clinical trials. [11] [12] [13] Despite a clear biological rationale for its use in the setting of AML, IFN-a has failed so far to live up to its expectations as solid clinical success has never been achieved.
Recent insights into the key determinants of the clinical efficacy of IFN, along with improvements in its pharmaceutical formulation, support reconsideration of its clinical utility in the treatment of AML. 14, 15 Careful retrospective analysis of all clinical trials performed hitherto reveals that IFN-a indeed has the potential to induce clinically relevant antileukemic responses in AML patients. Such responses, however, have only been observed in a minority of patients, which has raised questions about the factors responsible for this inconsistency. A major determinant of response to IFN-based therapy was recently uncovered in a murine xenograft model of human AML. Continuous delivery of type I IFN was found to be a critical factor for successful AML control, whereas intermittent IFN exposure did not result in a durable antileukemic response.
14 This requirement for constant, stable IFN levels is not likely to be met with naturally occurring IFN. 16 Clinical experience so far is mainly based on the use of these unmodified IFN formulations, hence providing a plausible explanation for the inconsistent and relatively modest clinical results achieved to date. 14 In recent years, IFN preparations with improved pharmacokinetic properties have been developed. Sustained serum IFN levels can nowadays be obtained by pharmacological modification of IFN, including genetic fusion of IFN-a with human serum albumin 17 or addition of a polyethylene glycol moiety (known as pegylation). 16, 18 On the basis of the results of the xenograft study described above, 14 it is highly expected that the use of these modified IFN preparations can unlock the therapeutic potential of IFN-a in acute leukemia. Pegylated IFN-a was recently put to the clinical test in a patient with AML superimposed on primary myelofibrosis. Weekly or biweekly subcutaneous administrations of pegylated IFN-a resulted in a durable complete hematological remission, so far persisting for 18 months. Importantly, treatment was performed on an outpatient basis and no major toxicity was observed. 15 This case study provides the clinical proof of concept that modified long-acting IFN-a can have significant antileukemic activity in vivo, andFtogether with the results of the xenograft studyFrekindles an old interest in the use of IFN-a as a therapy for AML.
After briefly highlighting the biological rationale behind the use of IFN-a as an antileukemic agent, this paper will review the clinical experience of IFN-a in AML and will seek to distill the factors responsible for the variety of responses observed so far.
Biological rationale behind the use of IFN-a in treatment of AML Numerous studies have provided strong evidence of antileukemic activity of type I IFN, which appears to result from a direct action on AML cells and from an indirect effect through immune activation.
Direct effects of type I IFN on AML cells
Type I IFNFIFN-a and IFN-bFhave the potential to produce a wide range of effects on human primary AML cells, including (1) inhibition of growth-promoting cytokines, (2) induction of apoptosis, (3) inhibition of cell proliferation and (4) enhancement of AML cell immunogenicity (Figure 1 ). Promotion of differentiation by IFN has also been observed in AML cell lines (Figure 1 ). These pleiotropic effects are mediated through binding of IFN-a to its receptor, which is expressed on the leukemic cell surface. 19 Binding triggers the activation of distinct signal transduction pathways, such as the Janus kinase/ signal transducers and activators of transcription (JAK/STAT) signaling pathway. 20 In addition to 'classical' JAK/STAT signaling, IFN-a has also been shown to engage other signal transduction pathways in AML cells (Figure 1 ). The relative contribution of each signaling pathway to the multifaceted action of IFN on AML cells is largely unknown. For instance, the p38 mitogen-activated protein kinase pathway is considered pivotal to the antiproliferative effect of IFN-a in CML, 21 while its precise role in AML remains to be investigated. Nevertheless, Figure 1 Molecular mechanisms of the pleiotropic effects of IFN-a on AML cells. Binding of IFN-a to its receptor (IFNAR) activates Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), which triggers the following signal transduction pathways in AML cells: JAK/STAT, 94, 95 p95 vav (Platanias and Sweet 96 ), Rac1/p38 mitogen-activated protein kinase (MAPK), 97 protein kinase C (PKC) 98 and insulin receptor substrate/phosphatidyl inositol 3-kinase (IRS/PI3K). 99, 100 Activation of these signaling pathways culminates in the transcription of IFN-inducible genes, whose concerted action initiates a complex series of molecular events underlying the pleiotropic effects of IFN. (1) Decrease in cytokine production. IFN-a decreases the autocrine production of the growth-promoting cytokines interleukin (IL)-1, IL-6, granulocyte macrophage colony-stimulating factor (GM-CSF) 101 and the pro-angiogenic cytokine IL-8 (Aman et al.
102
; Hatfield et al. 103 ). This effect is probably related to 2 0 ,5 0 -oligoadenylate synthetase (2 0 ,5 0 -OAS) induction, which activates RNaseL, resulting in RNA breakdown. 70, 104 (2) Induction of apoptosis. RNA degradation also leads to ribotoxic stress-induced apoptosis. 105 Caspase-8 is a key enzyme in the IFN-induced apoptosis, 106 activating downstream caspases and stimulating t-Bid/Bax-mediated cytochrome-c release from mitochondria (MC). 107 Fas/Fas ligand (Fas/FasL) [108] [109] [110] and tumor necrosis factor-a-related apoptosis-inducing ligand (TRAIL) 108 are involved in the IFN-induced upregulation of caspase-8. (3) Inhibition of cell proliferation. Rig-G prevents Jab-1-dependent degradation of p27 and upregulates p21 by downmodulating c-myc;
111 the latter has also been implicated in the apoptotic response to IFN. 112 The inhibitory effect of p21 and p27 on cyclin-dependent kinase 2 (Cdk2) results in a G1 to S transition arrest.
111
Downregulation of cyclin E further contributes to G1/S growth arrest. 113 Other cytostatic mechanisms include downregulation of human telomerase reverse transcriptase (hTERT) 114 and upregulation of the transcription factor PU.1 (Gutierrez et al. 115 ). (4) Increase in immunogenicity of AML cells. IFN-a, via PU.1, increases the expression of the proteinase 3/myeloblastin (MBN) tumor-associated antigen from which the immunogenic peptide PR1 is derived. 31 Recognition of AML cells by T cells is further enabled by the upregulation of major histocompatibility complex class I (MHC-I) molecules 109, 116 and CD86 (own unpublished observation). Increased expression of Fcg-receptors may contribute to antibody-dependent cellular cytotoxicity (ADCC). 117 20 Several of these intracellular mechanisms have been discovered in AML cell lines (Figure 1 ).
Indirect effects of type I IFN through immune activation
AML cells can also be targeted indirectly through the immunostimulatory action of type I IFN on dendritic cells (DC), T cells and natural killer (NK) cells, which are key players involved in the generation of an antileukemic immune response. 6, 22, 23 As summarized in Table 1 , antileukemic immune reactivity in AML patients may be critically impaired because of immune dysfunctions within these cell compartments ( Table 1 ). The ability of type I IFN to restore defective immune functions further adds to the biological rationale for use in AML therapy.
In vitro studies examining immunostimulatory effects on DC have indicated that human DC acquire cytolytic potential against myeloid leukemic cell lines following stimulation with type I IFN. [24] [25] [26] IFN-stimulated upregulation of TNF-a-related apoptosis-inducing ligand on DC is involved in DC-mediated killing of AML target cells. 24, 26 Several cytokines have been implicated in modulating DC function, type I IFN among them. 27, 28 They have been shown to enable cross-priming of naive T cells, both by licensing DC to present exogenous antigens in an immunostimulatory way and by acting directly on T cells (Table 1) . 29, 30 In addition to naive T cell priming, IFN-a can also contribute to the generation of an antigen-specific cytotoxic T cell response by promoting the endogenous expression of the leukemiaassociated antigen proteinase-3/myeloblastin in myeloid leukemic cells (Figure 1) . 31 Other effects of type I IFN on the T cell compartment are sensitization to interleukin-2-induced proliferation and promotion of survival, 32, 33 as well as enhancement of the cytotoxic properties of gd T cells against AML cells 34 (Table 1) . Finally, IFN-a has an important role in modulating NK cell function. NK cells are increasingly being recognized as essential components of the antileukemic immune response. 35, 36 Although these cells are able to recognize and eliminate AML blasts and even leukemic stem cells, 37 they often fail to do so effectively. [38] [39] [40] [41] [42] [43] [44] [45] [46] As summarized in Table 1 , several mechanisms may account for the defective cytotoxic effector function of NK cells in AML. [38] [39] [40] [41] [42] [43] [44] [45] [46] In this context, IFN-a again emerges as a potentially useful agent because there is strong evidence for its ability to harness the cytolytic activity of NK cells (Table 1) . 47 In addition, type I IFN can directly trigger the release of immunomodulatory cytokines from NK cells (for example, IFN-g), thereby potentiating the regulatory 'helper' function of these cells (Table 1) . 30, [48] [49] [50] [51] [52] This helper role of NK cells is important for the induction of DC with potent T helper type 1-polarizing capacity, which appears to be critical for antitumor immunity. 48, 51, 53 Moreover, the bidirectional cross-talk between NK cells and DC can further promote the activation status of both cell types. 22, 51, 54 Although conceptually interesting, the observation that type I IFN promote antileukemic immunity by targeting DC, T and NK cells is only relevant if this holds true for the situation in vivo. Studies of AML patients treated with IFN-a support the notion that these experimentally observed immunostimulatory effects may also be of clinical significance. In this regard, it was shown that IFN-a may potentiate immune-mediated graftversus-leukemia reactions following allogeneic hematopoietic stem cell transplantation (HSCT). [55] [56] [57] [58] [59] [60] [61] [62] Graft-versus-leukemia results from a complex interplay between various immune cells, including DC, T cells and NK cells, 63 which are all susceptible to immunostimulatory action of IFN, as described above. Increase in T cell stimulatory and cross-priming capacity of DC 6, 30 Differentiation, phenotypic maturation and activation 6, 30 Cytotoxic capacity Not examined Increase in cytotoxic capacity against leukemic cells [24] [25] [26] Partly dependent on upregulation of TRAIL 24, 26 T 
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Evidence that IFN-a can elicit clinically relevant immune responses in AML patients was provided by Lowdell et al., [64] [65] [66] [67] who observed an association between IFN-induced recovery of NK cell cytolytic function and achievement of sustained complete remission in two AML patients treated with IFN-a.
Clinical experience with IFN-a in AML
Clinical activity of IFN-a in AML Clinical attempts to use IFN-a in the treatment of AML were already made in the mid-1960s and in the early 1970s (Falcoff et al. 68 ; Ahstrom et al. 69 ). While these pioneer studies did not allow to draw direct conclusions on its therapeutic value, the first evidence of in vivo antileukemic activity was provided by Hill et al. in 1979. 10 As shown in Table 2 , the clinical experience with IFN-a in AML can be divided into three categories. The first group comprises patients with primary or relapsed AML to whom IFN-a has been administered with the aim of inducing remission. In the second group, IFN-a has been used as salvage therapy for AML relapse following HSCT. In a third group of patients, who were brought in complete remission with conventional treatment modalities (chemotherapy and/or HSCT), the goal of IFN-a therapy was to control minimal residual disease (MRD) and to prevent relapse.
Overall, the evidence on IFN-a as treatment option for AML is generally derived from single case studies or small, nonrandomized phase I/II trials. For several reasons, a comparative analysis of the studies presented in Table 2 is a challenge. First, different IFN-a preparations have been used, making direct comparisons difficult. 70 In the early clinical trials, impure and poorly characterized IFN preparations were derived from peripheral blood leukocyte cultures (human leukocyte IFN) or from lymphoblast cell lines (human lymphoblastoid IFN) . 71 The advent of recombinant DNA technology paved the way for standardized recombinant human IFN-a preparations, with subtypes 2a and 2b becoming available for clinical use. 71, 72 Second, the therapeutic action of IFN-a has not only been studied in monotherapy, but also in combination with a range of other therapeutic agents. For example, in the context of posttransplantation relapse of AML, combinations of IFN-a with chemotherapy, cytokines (granulocyte macrophage colonystimulating factor, interleukin-2) and/or donor lymphocyte infusions have been tested. Third, as indicated in Table 2 , there is a considerable inter-study variability with respect to the route Table 2 Treatment results of IFN-a therapy in AML patients r-IFN-a-2a SC: 3 MU, 2-3qw Â 3-56w Continued CR (7) Ratanatharathorn et al. Abbreviations: AML, acute myeloid leukemia; ara-C, cytosine arabinoside; (c)IV, (continuous) intravenous; CR, complete remission; CT, chemotherapy; DFS, disease-free survival; DI, differentiation inducers (for example, retinoic acid, vitamin D3); DLI, donor lymphocyte infusions; GM-CSF, granulocyte macrophage colony-stimulating factor; IM, intramuscular; IFN, interferon; IL, interleukin; Le-, leukocyte; Ly-, lymphoblastoid; MU, Â 10 6 units; NE, not evaluable; NR, no response; OS, overall survival; peg-, pegylated; PR, partial response; qd, per day; qw, per week; r-, recombinant; nos, not otherwise specified; RR, relapse rate; SC, subcutaneous; x, for. The numbers between parentheses in the 'Clinical response' column represent the number of patients with the clinical effect observed.
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of IFN-a administration (intramuscular, intravenous or subcutaneous), dose, frequency and duration of treatment. Although these factors make it difficult to combine the results of the individual studies performed hitherto, there is definitive proof that IFN-a has antileukemic activity in selected AML cases (Table 2) . Different studies have indeed demonstrated substantial antileukemic effects in vivo, ranging from temporary blast cytoreduction to induction of durable complete remissions. Interestingly, these results have mainly been obtained in AML patients with poor prognostic features (age above 60, AML refractory to chemotherapy/HSCT, relapse, secondary AML), which further highlights the therapeutic potential of IFN-a for the treatment of AML. In addition to its activity in patients with an established diagnosis of AML, it has also been suggested that IFN-a may inhibit the evolution of primary myelofibrosis into AML. 73 Although there is clear evidence that IFN-a can induce relevant antileukemic responses in vivo, its clinical utility in the setting of AML has not been consistently established. This raises questions about the factors responsible for the inconsistent and rather modest clinical results achieved so far, which will be discussed in detail in the next section.
Heterogeneity in clinical outcome
The variability in clinical outcome can, at least in part, be explained by the different dose regimens of IFN-a that have been applied. Early studies of low-dose IFN-a failed to objectively demonstrate antileukemic responses, 69, 74 the first clinical success was achieved after high-dose continuous intravenous administration of IFN-a 10 ( Table 2) . Although some reports have suggested that low-dose IFN-a might be effective in AML, 75 the majority of the studies have indicated an association between IFN-a dosage and therapeutic efficacy. In a small case series, Hill et al.
10,76 observed a temporary blast cytoreduction in all but one of the patients receiving daily intravenous doses of 40.5 MU/kg IFN-a, whereas no demonstrable effect was observed in the lower dose range. Interestingly, it was shown that upward dose adjustment in a low-dose-treated patient could lead to the induction of an antileukemic response, indicative of a dose-dependent action of IFN-a. 76 A similar dose-related efficacy was suggested by Mirro et al. 77 (Table 2) . In this study, the five responding patients with decreased peripheral blood blast cell counts were all treated with high-dose IFN-a (420 MU/m 2 /day). No clear antileukemic effects were observed at lower doses. 77 The suggestion of a concentration-effect association raises questions about the serum levels of IFN-a needed to obtain adequate activity against AML in vivo. Pharmacokinetic studies have indicated that a minimum effective serum level of around 1000 IU/ml is required for an antileukemic effect (that is, a transient decline in circulating AML blasts). 78 In vitro, a concentration of 1000 IU/ml is sufficient to inhibit clonogenic AML cell growth by 50%, but a definitive abrogation of the malignant cell proliferation is not observed under such conditions. 14, 78 This provides a plausible explanation for the transient and partial antileukemic effects occurring at serum levels of 1000 IU/ml. 78 In the same study, pharmacokinetic analysis was performed in the single responder who had a dramatic decrease in bone marrow blasts from 99% to normal values, under IFN-a therapy. It was found that this antileukemic response had been generated at a mean serum IFN-a level exceeding 3000 IU/ml. 78 Interestingly, the early observation that a minimum concentration of 3000 IU/ml is required for adequate control of the leukemic process in vivo, has been recently confirmed in the aforementioned human AML xenograft model.
14 It is also important to consider intersubject variability in serum IFN values following administration of a fixed dose of IFN-a. In healthy volunteers, intravenous administration of 32 MU IFN-a-2a resulted in highly divergent C max levels ranging from 8.6 to 17.6 ng/ml, 16 corresponding to 1500-4500 IU/ml. 79 A similar disparity has been observed among patients with AML, where clinically effective doses of IFN-a (420 MU/m 2 ) led to inconsistent and largely unpredictable peak serum levels. 77 It is therefore tempting to speculate that these interindividual variations in serum IFN levels contributed to the heterogeneous clinical results obtained so far.
Not only are there appreciable differences in serum IFN concentrations between AML patients receiving IFN-a, a great deal of interindividual variability also seems to be derived from the susceptibility of AML cells to the antiproliferative action of IFN. Evidence for such heterogeneity is derived from in vitro studies, showing varying degrees of IFN sensitivity among different AML cell lines and primary AML blasts. 19, 78 In a study by Gallagher et al., 80 clonogenic assays with leukemic blasts of IFN-a-treated AML subjects demonstrated no evidence of growth inhibition in more than half of the cases. In the remaining responders, the concentrations required for a 50% growth inhibition varied from 500-3000 IU/ml, suggestive of an inter-individual difference in susceptibility to the antiproliferative action of IFN-a. Although a correlation between in vitro sensitivity and in vivo antileukemic efficacy was not clearly evident from both studies, 78, 80 it is conceivable that the mixed clinical responses observed so far also result from individual differences in IFN responsiveness at the cellular level. It remains to be determined, however, whether in vitro growth inhibition patterns could allow the identification of individual patients who are more likely to benefit from IFN-a therapy, 18 because indirect immunological effects can also contribute to the effect of systemic IFN-a therapy, as described above.
Another potentially important pharmacokinetic determinant of clinical efficacy was recently uncovered by Benjamin et al.
14
In a murine xenograft model of human AML, the investigators observed that sustained enforced expression of type I IFN is essential for obtaining sufficient leukemia control in vivo, while intermittent exposure of AML cells to type I IFN had no detectable effect. Unmodified IFN-a preparations, which were used in most clinical trials conducted so far, have notoriously short half-lives resulting in transient and rapidly declining serum IFN concentrations. 16, 77 As can be predicted from the xenograft model, their pharmacokinetic profile is unlikely to induce durable antileukemic effects in vivo.
14 This pharmacokinetic shortcoming can be addressed by using pharmacologically modified IFN preparations, such as pegylated IFN-a. 16, 18 A single subcutaneous dose of 180 mg of pegylated IFN-a-2a results in steady-state serum IFN levels within the antileukemic range (20-25 ng/ml or 6000 IU/ml) that remain stable for 1 week. 16, 79 Although most clinical experience with pegylated IFN-a was obtained in chronic viral hepatitis B and C, its place in the treatment of myeloid malignancies is increasingly being recognized. 9 Recent studies have underscored the therapeutic value of pegylated IFN-a in CML 81 and other myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia and primary myelofibrosis). [81] [82] [83] [84] [85] [86] Preliminary data are available on its clinical use in AML; a recent case study by our group has illustrated the therapeutic potential of pegylated IFN-a in the setting of AML. 15 This was demonstrated by the induction of a long-lasting complete remission in a poor-prognosis AML superimposed on a preceding state of primary myelofibrosis.
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This observation supports the concept that maintaining stable serum IFN levels may be crucial to clinical efficacy, as was observed in the xenograft study by Benjamin et al.
14
Heterogeneous patient characteristics could also represent a possible source for the mixed results with IFN-a for AML therapy. As shown in Table 2 , IFN-a therapy has been applied in different clinical settings. However, most of the cases included belong to a group of patients with advanced disease and/or an overall poor prognosis (for example, age 460, chemotherapyrefractory cases, secondary AML, previous relapse or relapsed AML following HSCT). It is evident that these unfavorable patient characteristics may have influenced the clinical outcome, thus interfering with an accurate evaluation of the therapeutic potential of IFN-a. In such patients even minor improvements in clinical outcome or major responses in only a limited number of patients must be considered as meaningful and clinically relevant.
Few reports have addressed the potential effect of IFN-a in the context of MRD. In the Brown Norway rat leukemia model, a well-established preclinical model for the study of human AML, IFN-a treatment enabled the control of MRD and led to a significant extension of the median survival time. Moreover, a relationship between total IFN-a dosage and survival benefit was suggested. 87 Early enthusiasm for the use of IFN-a in the setting of MRD was tempered by the results of clinical studies that failed to substantiate its clinical efficacy (Table 2 ). In patients with AML who entered complete remission following induction and consolidation chemotherapy, additional maintenance therapy with low-dose IFN-a did not succeed in preventing leukemic relapse and improving the prognosis. 88 Similar negative results were obtained in the United Kingdom Medical Research Council AML-11 trial, where IFN-a maintenance treatment failed to demonstrate a clear benefit in terms of relapse rate, disease-free survival and overall survival. 89 It should be taken into consideration, however, that the IFN-a dose used in both trials may have been suboptimal, leading to undertreatment. Moreover, in the AML-11 trial, 475% of the patients randomized to receive IFN-a did not complete the designated treatment period of 12 months. 89 The total length of therapy may thus have been too short to bring about sufficient control of MRD, making it difficult to draw any firm conclusions.
The optimal duration of IFN-a treatment in acute leukemia has not yet been adequately established. However, previous studies in other hematological malignancies have indicated that prolonged therapy might be critical to clinical success. The SPIRIT phase III trial of the French CML group, which compared the efficacy of pegylated IFN-a-2a plus imatinib versus imatinib alone for de novo CML, revealed that the duration of IFN-a treatment may have a major impact on therapeutic response. Extended treatment with pegylated IFN-a-2a for 41 year resulted in significantly higher molecular response rates as compared with short-term treatment (o4 months). 81 Similarly, a minimum treatment period of 6 months was recommended for IFN-a to be fully effective in myelodysplastic syndromes. 90 Remarkably, clinical improvement in two myelodysplastic syndrome patients was observed several months after discontinuation of IFN-a, which was suggested to be the result of a delayed antineoplastic action. 90 Similar late responses have not been observed in the setting of AML, where an antileukemic effect usually occurred in close temporal relationship with the start of IFN-a treatment. 56, 58 Preisler et al. 91 have shown that IFN-a almost instantly inhibits the proliferative rate of AML blasts in vivo. The same pattern applies for the activation of the host immune system by IFN-a. Lowdell et al. 64 demonstrated a rapid induction of NK cell-mediated antileukemic immunity early after initiation of IFN-a therapy in two AML patients. While IFN-a thus seems to have a relatively rapid onset of action in AML, it remains to be determined for how long IFN-a therapy should be continued. In the context of post-transplantation relapse of AML, reports have indicated that persistent remissions can be obtained despite cessation of IFN-a after a relatively short period of treatment, ranging from a few weeks 57 to several months. 57, 90 However, extended treatment was required in some cases to achieve a full and persistent response. In our recently published case study, a complete remission was only achieved after 5 (but not 2) months of continued administration of pegylated IFN-a-2a. 15 Further study is required to determine whether prolonged therapy might be one of the keys to clinical success in AML, analogous to the situation in CML.
In addition, the most opportune moment to initiate treatment with IFN-a in AML is not clearly defined. Several studies have suggested that IFN-a should preferably be started in leukemia patients with relatively low tumor burden. 55, 57, 59, 62 Hence, the inclusion of patients with an advanced disease process and/or a high leukemic cell load could explain some of the heterogeneity in patient outcome across the studies conducted so far (Table 2) . Therefore, the optimal timing of IFN-a therapy for AML merits special attention in future clinical trials. 62 
Toxicity in humans
The toxicity profile of IFN-a has recently been extensively reviewed by Kiladjian et al. 9 It will therefore not be discussed in further detail here, except to mention the increased risk of graftversus-host disease in the context of IFN-a therapy for posttransplantation relapse of AML. 55, 56, [60] [61] [62] 75 Anecdotic reports and small case series have indeed indicated that IFN-a-based immunotherapy may represent an effective treatment option for relapsed leukemia after allogeneic HSCT, eliciting graft-versusleukemia effects and durable clinical responses (Table 2) . However, induction of graft-versus-leukemia is generally associated with development of graft-versus-host disease. 62 Nevertheless, empirical treatment with IFN-a, either alone or in combination with donor lymphocyte infusions, seems to be justified in the context of post-transplantation AML relapse because of the lack of effective treatment alternatives. 61 Modified, long-acting IFN preparations can improve the toxicity profile of IFN-a. 9, 92 This further underscores why this cytokine may represent a clinically viable therapeutic option, especially for elderly AML patients who are often deemed unfit for aggressive polychemotherapy.
2,15
Conclusions and future prospects Through expression of the IFN-a receptor and different signal transduction molecules, AML cells can respond to IFN-a, resulting in induction of apoptosis and differentiation, inhibition of proliferation and increased immunogenicity. In addition, type I IFN activates DC, T cells and NK cells and thus contribute to the generation of a potent antileukemic immune response. The dual action of IFN-a both on AML cells and on multiple components of the immune system underscores the therapeutic potential of IFN-a in AML.
Despite the potential for clinically important effects in patients with AML, clinical trials with IFN-a have so far only shown modest results. Several determinants could have contributed to these heterogeneous clinical results, as discussed above. The need to obtain sustained and sufficiently high serum IFN concentrations for adequate antileukemic control may be the main critical factor for therapeutic success. New pharmaceutical long-acting formulations, such as pegylated IFN or albumin-IFN fusion proteins, are compatible with this pharmacokinetic consideration and support revived expectations of IFN-a therapy in AML. 15 New clinical trials are needed to address several unanswered questions, including which immune cells become activated by IFN-a in AML. Preclinical studies on combinations of IFN-a and other antileukemic agents offer new opportunities for improving its clinical applicability. 56, 80 Such combinatorial approaches have also been reported to be successful in AML patients relapsing after HSCT, 93 arguing for the exploration of new combination regimens. Future research should also focus on identifying the maximally effective IFN treatment scheme with respect to optimal dose, timing and treatment duration. Furthermore, it remains elusive which specific AML patient groups will benefit from IFN-a therapy. The overall acceptable toxicity, however, supports the concept that IFN-a might be considered as an alternative option for AML secondary to myeloproliferative neoplasm or elderly AML patients who are unable or unwilling to tolerate aggressive polychemotherapy. The limited efficacy of chemotherapy in these categories of AML patients further illustrates why IFN-a could carve its therapeutic niche in selected cases of AML.
